3 Medical Instruments Stocks Using GenAI to Navigate Industry Woes

Moumi Mondal October 05, 2026

ISRG TMO GMED

Better trading starts here.

What would you like to follow?

Industry Outlook

Cancel

Industry Description

The Zacks Medical - Instruments industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas. This FDA-regulated sector encompasses a vast array of products, from transcatheter valves and orthopedic devices to advanced imaging equipment and robotics. Recent trends highlight the integration of AI in diagnostics, the expansion of telemedicine, the rise of robotic-assisted surgeries and developments in 3D printing, continuous glucose monitoring systems and gene editing. The rise of GenAI is also reshaping MedTech, from speeding up patient recruitment to optimizing trial designs and improving regulatory processes. The FDA’s Total Product Life Cycle approach supports faster development of safe and effective medical devices critical to public health.

3 Trends Shaping the Future of the Medical Instruments Industry

GenAI Revolution: Over the past couple of years, GenAI adoption in the medical instrument space has increased significantly,with hyper-personalization being the primary feature of GenAI-driven treatment options. By analyzing vast and complex genetic and molecular data, GenAI is expected to help healthcare reach new heights in terms of predictive treatment options and smart hospital systems. According to Grand View Research, the global GenAI in healthcare market is projected to witness a 33.3% CAGR between 2026 and 2033. Rising demand for personalized healthcare solutions is driving growth, with GenAI enabling tailored treatment plans, more accurate diagnoses and streamlined administrative tasks. AI-driven documentation tools integrated into leading EHR platforms are also accelerating adoption by streamlining physician workflows, reducing manual data entry, improving documentation accuracy and easing burnout. AI applications in diagnostics are expanding rapidly, with the market expected to expand at a 46.1% CAGR through 2034.

M&A Trend: The medical instrument space has been benefiting from the ongoing merger and acquisition (M&A) trend. Smaller and midsized companies are turning to consolidation to gain scale and strengthen their competitive position, while larger players are pursuing acquisitions to enter niche markets and add specialized products and technologies to their portfolios. According to PWC’s Medtech: US Deals 2026 midyear outlook, Medtech M&A remained strong in the first half of 2026, supported by large strategic and sponsor-backed deals and sustained interest in high-growth categories. Deal value totaled $36.5 billion, following a decade-high level of M&A activity in 2025. Key transactions included Boston Scientific’s $15 billion agreement to acquire Penumbra and Danaher’s $10 billion acquisition of Masimo. M&A momentum in the second half of 2026 continues to be supported by investments in innovation-led areas such as cardiovascular and neurostimulation, connected care and workflow platforms, as well as ongoing carve-outs, take-privates and other portfolio reshaping activity.

Business Trend Disruption: The IMF’s July 2026 World Economic Outlook projects global growth of 3% in 2026 and 3.4% in 2027, below the 3.5% average observed in 2024-25 but broadly unchanged from its April forecast on a cumulative basis. The outlook remains uneven, with the Middle East war shock weighing on energy importers and vulnerable economies, while AI-driven demand supports countries integrated into the global technology value chain. The impact varies based on countries’ exposure to the conflict and their role in the technology supply chain. Global headline inflation is expected to rise from 4.1% in 2025 to 4.7% in 2026 before easing to 3.9% in 2027. The projections were revised slightly higher from April, suggesting that the disinflation trend that began in early 2024 has stalled. The prospect of renewed conflict in the Middle East remains and could extend commodity price volatility, disrupt supply chains, raise prices and weigh on financial conditions.

Zacks Industry Rank Indicates Bright Prospects

The Zacks Medical Instruments industry’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates upbeat near-term prospects. The industry, housed within the broader Zacks Medical sector, currently carries a Zacks Industry Rank #86, which places it in the top 35% of 247 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

We will present a few stocks that have the potential to outperform the market based on a strong earnings outlook. It is worth taking a look at the industry’s shareholder returns and current valuation first.

Industry Underperforms S&P 500 & Sector

The industry has lagged the Zacks S&P 500 composite and the sector over the past year. The industry has gained 2.7% compared with the broader sector’s rise of 4.1%. The S&P 500 has returned 15.4% in a year.